EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing Antidiabetic Medications for Parkinson’s Disease: Focus on Biomarker Strategies for Disease Modification

Narayana K Yelleswarapu iD, Christos Sidiropoulos

International Journal of Molecular Sciences · 11.03.2026 · 27 (6) · 2560

DOI: 10.3390/ijms27062560 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.03.2026. Verfasst von Narayana K Yelleswarapu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Ophthalmology, Michigan State University, East Lansing, MI 48824, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Hypoglycemic Agents, Drug Repositioning, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. It shares many pathophysiologic similarities with type 2 diabetes mellitus (T2DM). Numerous studies have explored the repurposing of antidiabetic medications for their potential neuroprotective effects in PD. There has not been a consolidated review of the biochemical biomarkers that have been evaluated across antidiabetic medications. This review aims to assess the current landscape of biomarker research in evaluating the efficacy of these antidiabetic agents as disease-modifying therapies in PD. We examine the molecular mechanisms targeted by these drugs, the biomarkers used to assess their effects, and the outcomes of clinical trials. This review hopes to identify gaps in current research and enhance the evaluation of antidiabetic medications in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHypoglycemic AgentsDrug RepositioningBiomarkersHumansAnimalsDiabetes Mellitus, Type 2Neuroprotective Agents

Stichwörter der Autor:innen

Parkinson’s diseaseantidiabetic medicationsbiochemical biomarkersdisease-modifying therapies

Substanzen

Hypoglycemic AgentsBiomarkersNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Neurology and Ophthalmology, Michigan State University, East Lansing, MI 48824, USA.

ORCID-Profile: Narayana K Yelleswarapu

Zitieren

APA

Yelleswarapu, N. K., & Sidiropoulos, C. (2026). Repurposing Antidiabetic Medications for Parkinson’s Disease: Focus on Biomarker Strategies for Disease Modification. International Journal of Molecular Sciences, 27(6), 2560. https://doi.org/10.3390/ijms27062560

Vancouver

Yelleswarapu NK, Sidiropoulos C. Repurposing Antidiabetic Medications for Parkinson’s Disease: Focus on Biomarker Strategies for Disease Modification. International Journal of Molecular Sciences. 2026;27(6):2560. doi:10.3390/ijms27062560

BibTeX
@article{Yelleswarapu2026,
  author = {Yelleswarapu, Narayana K and Sidiropoulos, Christos},
  title = {Repurposing Antidiabetic Medications for Parkinson’s Disease: Focus on Biomarker Strategies for Disease Modification},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {2560},
  doi = {10.3390/ijms27062560}
}
Kostenlos starten →